Dimensional Fund Advisors
SPRO icon

Dimensional Fund Advisors’s Spero Therapeutics SPRO Stock Holding History

Dimensional Fund Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
274,820
+245,052
+823% +$641K ﹤0.01% 2944
2026
Q1 		$69.2K Hold
29,768
– – ﹤0.01% 3148
2025
Q4 		$69K Buy
29,768
+774
+3% +$1.8K ﹤0.01% 3191
2025
Q3 		$54.9K Buy
+28,994
New +$63.8K ﹤0.01% 3236
2025
Q1 		– Sell
-10,003
Closed -$10.3K – 3353
2024
Q4 		$10.3K Hold
10,003
– – ﹤0.01% 3334
2024
Q3 		$13.4K Hold
10,003
– – ﹤0.01% 3342
2024
Q2 		$13K Hold
10,003
– – ﹤0.01% 3361
2024
Q1 		$17.2K Hold
10,003
– – ﹤0.01% 3372
2023
Q4 		$14.7K Sell
10,003
-1,750
-15% -$2.09K ﹤0.01% 3399
2023
Q3 		$14.2K Hold
11,753
– – ﹤0.01% 3452
2023
Q2 		$17K Hold
11,753
– – ﹤0.01% 3455
2023
Q1 		$17K Buy
+11,753
New +$19.7K ﹤0.01% 3443
2022
Q3 		$20K Sell
10,003
-274,953
-96% -$273K ﹤0.01% 3463
2022
Q2 		$212K Sell
284,956
-121,990
-30% -$355K ﹤0.01% 3243
2022
Q1 		$3.54M Buy
406,946
+35,724
+10% +$366K ﹤0.01% 2641
2021
Q4 		$5.94M Buy
371,222
+41,589
+13% +$661K ﹤0.01% 2509
2021
Q3 		$6.07M Sell
329,633
-44,810
-12% -$719K ﹤0.01% 2523
2021
Q2 		$5.23M Buy
374,443
+31,937
+9% +$446K ﹤0.01% 2595
2021
Q1 		$5.04M Buy
342,506
+92,309
+37% +$1.62M ﹤0.01% 2581
2020
Q4 		$4.85M Buy
250,197
+19,188
+8% +$299K ﹤0.01% 2541
2020
Q3 		$2.58M Buy
231,009
+16,854
+8% +$199K ﹤0.01% 2671
2020
Q2 		$2.9M Buy
214,155
+15,294
+8% +$172K ﹤0.01% 2633
2020
Q1 		$1.61M Buy
198,861
+43,381
+28% +$382K ﹤0.01% 2779
2019
Q4 		$1.5M Buy
155,480
+32,475
+26% +$350K ﹤0.01% 2929
2019
Q3 		$1.3M Buy
123,005
+16,602
+16% +$175K ﹤0.01% 2953
2019
Q2 		$1.22M Buy
106,403
+88,534
+495% +$1.07M ﹤0.01% 3011
2019
Q1 		$229K Buy
+17,869
New +$190K ﹤0.01% 3287

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors's SPRO Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Spero Therapeutics (SPRO) stake by 823% in Q2 2026, buying an estimated $641K and bringing the position to 274,820 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

Dimensional Fund Advisors first reported a position in SPRO in Q1 2019 and has held it in 27 quarters since. The position peaked at $6.07M in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Dimensional Fund Advisors held 274,820 shares of Spero Therapeutics worth $608K as of Q2 2026.
  • Dimensional Fund Advisors bought 245,052 Spero Therapeutics shares in Q2 2026, an estimated $641K.
  • Spero Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2944 holding.
  • Dimensional Fund Advisors first reported a position in Spero Therapeutics in Q1 2019 and has held it in 27 quarters since.
  • Dimensional Fund Advisors's Spero Therapeutics position peaked at $6.07M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.